Latest Headlines

  1. Nona Biosciences And Atossa Therapeutics Partner To Discover Next-Generation Antibody Therapies For Breast Cancer 4/10/2025

    Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona's proprietary H2L2 Harbour Mice® platform to identify next-generation therapeutic candidates for breast cancer.

  2. Signios Bio Launches With AI-Driven Bioinformatics And Advanced Multiomics Platform To Power The Future Of Precision Medicine And Drug Discovery 4/10/2025

    Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc.

  3. BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies To Anti-Cancer Target B7-H3 4/10/2025

    BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel, high affinity antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques.

  4. Renovaro And BioSymetrics Close Merger To Accelerate AI-Driven Biomarker Discovery And Precision Medicine 4/9/2025

    Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025.

  5. Kura Oncology And Kyowa Kirin Announce Submission Of New Drug Application For Ziftomenib To FDA 4/8/2025

    Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”), today announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM 1) mutation to the U.S. Food and Drug Administration (FDA) on March 31, 2025.

  6. Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran (Del-Desiran) For Treatment Of Myotonic Dystrophy Type 1 4/8/2025

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies.

  7. Tenpoint Therapeutics Ltd. Submits New Drug Application To U.S. FDA For BRIMOCHOL PF For The Treatment Of Presbyopia 4/8/2025

    Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million people in the United States.

  8. Engine Biosciences And Experimental Drug Development Centre Partner To Advance Novel Therapies To Combat Cancer 4/8/2025

     Engine Biosciences (Engine), a Singapore- and Silicon Valley-based biotechnology company pioneering precision medicine for cancer, announced a new partnership with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR).

  9. CytoTronics Launches Neural Application For Pixel, Unleashing High-Throughput Screening Capability In Drug Discovery For Neurological Disease 4/8/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched its Neural application for Pixel systems today. A pioneering innovation for neurodegenerative disease and neurotoxicity research, the application enables high-throughput screening for drug discovery at unprecedented scale.

  10. New Drug Submission For AGAMREE® (Vamorolone) Accepted For Priority Review By Health Canada For The Treatment Of Duchenne Muscular Dystrophy 4/8/2025

    Kye Pharmaceuticals, Inc. ("Kye") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of AGAMREE® (vamorolone). If approved, AGAMREE® would be the first and only therapy approved by Health Canada with an indication for the treatment of Duchenne muscular dystrophy (DMD).